The Fibrinogen/Albumin Ratio Index as an Independent Prognostic Biomarker for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgery.
combined hepatocellular cholangiocarcinoma
fibrinogen-to-albumin ratio
prognosis
surgery
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
02
2022
accepted:
07
05
2022
entrez:
31
5
2022
pubmed:
1
6
2022
medline:
1
6
2022
Statut:
epublish
Résumé
The fibrinogen/albumin ratio (FAR) is increasingly considered as a potential biomarker for predicting prognosis in various malignant tumors, whereas the value of the FAR in predicting the recurrence-free survival (RFS) in patients with combined hepatocellular cholangiocarcinoma (cHCC-CCA) after surgery has not been studied. A total of 104 patients with surgical-pathologically proved cHCC-CCA were retrospectively analyzed. The best cut-off value of the FAR was calculated via receiver operating characteristic (ROC) curve analysis, and the cohort was then divided into two groups as high-FAR (H-FAR) group and low-FAR (L-FAR) group. The correlation between the preoperative FAR and clinicopathological characteristics was analyzed. Uni- and multi-variable analyses for RFS were evaluated using a Cox proportional hazards model to verify the predictive value of FAR on the RFS of cHCC-CCA. Additionally, a novel clinical nomogram based on FAR was developed to preoperatively predict the RFS of HCC-CCA. The C-index and calibration were conducted to evaluate the performance of the developed nomogram. According to the cut-off value of the FAR, the patients were grouped into the H-FARI (>0.075) and L-FARI (≤0.075) groups. FAR was significantly correlated with several clinical-pathological features, including age, cirrhosis, AFP, CA19-9, BCLC staging, NLR, and PLR. In the multi-variate analysis, FAR, cirrhosis and tumor size were independent prognostic predictors for poor RFS in cHCC-CCA patients after surgery. Moreover, the clinical nomogram based on FAR was constructed, showing well-predictive accuracy. The preoperative FAR is a convenient and feasible serum biomarker for predicting the RFS of cHCC-CCA after surgery. Such developed FAR-based nomogram integrating tumor size and cirrhosis could be served as a feasible and convenient tool to assist the decision-making of clinical strategy.
Identifiants
pubmed: 35637941
doi: 10.2147/CMAR.S361462
pii: 361462
pmc: PMC9143788
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1795-1806Informations de copyright
© 2022 Xu et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Cancer Manag Res. 2021 Apr 12;13:3181-3192
pubmed: 33883935
World J Surg Oncol. 2020 Dec 4;18(1):319
pubmed: 33276780
World J Hepatol. 2020 Nov 27;12(11):1020-1030
pubmed: 33312426
Cell Death Dis. 2020 May 4;11(5):313
pubmed: 32366840
Cancer Manag Res. 2021 Aug 06;13:6157-6167
pubmed: 34385843
Korean J Radiol. 2020 Oct;21(10):1115-1125
pubmed: 32729276
Onco Targets Ther. 2021 Dec 07;14:5403-5415
pubmed: 34908845
Ann Surg Treat Res. 2021 May;100(5):260-269
pubmed: 34012943
Aging (Albany NY). 2020 Aug 13;12(15):15334-15358
pubmed: 32788423
Mol Med. 2020 Jun 17;26(1):60
pubmed: 32552682
Front Oncol. 2021 Oct 25;11:731993
pubmed: 34760694
World J Surg Oncol. 2021 Jul 20;19(1):218
pubmed: 34284775
Ann Transl Med. 2021 Oct;9(20):1518
pubmed: 34790724
Cancer Cell. 2019 Jun 10;35(6):932-947.e8
pubmed: 31130341
Liver Int. 2021 Jun;41 Suppl 1:73-77
pubmed: 34155790
Mod Rheumatol. 2016;26(3):372-6
pubmed: 26403379
Int J Oncol. 2020 Jul;57(1):54-66
pubmed: 32236573
Asian J Surg. 2021 Nov;44(11):1389-1395
pubmed: 33766528
Transl Lung Cancer Res. 2019 Dec;8(6):886-894
pubmed: 32010567
J Immunol Res. 2018 May 22;2018:4925498
pubmed: 30027102
Cancers (Basel). 2020 Mar 26;12(4):
pubmed: 32224916
Cells. 2020 Jun 01;9(6):
pubmed: 32492896
Lung Cancer. 2017 Sep;111:176-181
pubmed: 28838390
Hepatol Res. 2020 Jul;50(7):863-870
pubmed: 32335986
Eur Radiol. 2022 Jan;32(1):78-88
pubmed: 34279688
Hepatobiliary Pancreat Dis Int. 2020 Dec;19(6):515-523
pubmed: 32753331
BMC Cancer. 2020 Jul 10;20(1):642
pubmed: 32650743
Eur J Clin Invest. 2019 Jan;49(1):e13037
pubmed: 30316204
Ann Surg. 2021 Dec 1;274(6):e1187-e1195
pubmed: 31972643
Cancer Manag Res. 2021 Jan 08;13:107-115
pubmed: 33447083
J Hepatol. 2021 May;74(5):1212-1224
pubmed: 33545267
Ann Diagn Pathol. 2019 Feb;38:126-137
pubmed: 30597357
Cancer Manag Res. 2021 May 24;13:4169-4180
pubmed: 34079370